Table 2.
Demographics of patients with nCRT.
| Before propensity score matching | After propensity score matching | |||||
|---|---|---|---|---|---|---|
| Open (n = 71) |
MIS (n = 42) |
p | Open (n = 42) |
MIS (n = 42) |
p | |
| Age (years, median ± (SD) | 57 ± 12 | 55 ± 10 | 0.341 | 58 ± 12 | 55 ± 10 | 0.158 |
| Sex, n (%) | 0.846 | 0.503 | ||||
| Male | 42 (59.2) | 24 (57.1) | 27 (64.3) | 24 (57.1) | ||
| Female | 29 (40.8) | 18 (42.9) | 15 (35.7) | 18 (42.9) | ||
| BMI (kg/m2) | 23.1 ± 3.6 | 23.3 ± 4.7 | 0.839 | 22.7 ± 2.6 | 23.3 ± 4.7 | 0.123 |
| ASA score, n (%) | 1.000 | 1.000 | ||||
| < 3 | 70 (98.6) | 42 (100.0) | 41 (97.6) | 42 (100.0) | ||
| ≥ 3 | 1 (1.4) | 0 (0.0) | 1 (2.4) | 0 (0.0) | ||
| Underlying, n (%) | 33 (46.5) | 17 (40.5) | 0.562 | 24 (57.1) | 17 (40.5) | 0.127 |
| HTN | 23 (32.4) | 12 (28.6) | 0.682 | 16 (38.1) | 12 (28.6) | 0.355 |
| DM | 7 (9.9) | 9 (21.4) | 0.101 | 4 (9.5) | 9 (21.4) | 0.131 |
| IHD | 3 (4.2) | 1 (2.4) | 1.000 | 2 (4.8) | 1 (2.4) | 0.500 |
| COPD | 8 (11.3) | 0 (0.0) | 0.025 | 7 (16.7) | 0 (0.0) | 0.012 |
| Preoperative CEA (ng/mL) | 2.1 ± 2.7 | 2.7 ± 2.7 | 0.268 | 2.5 ± 3.0 | 2.7 ± 2.7 | 0.778 |
| Preoperative CA19-9 (ng/mL) | 14.3 ± 21.6 | 13.3 ± 12.0 | 0.241 | 11.6 ± 6.0 | 13.3 ± 12.0 | 0.367 |
| Tumor distance from AV (cm) | 3.0 ± 1.3 | 2.9 ± 1.7 | 0.485 | 2.6 ± 1.1 | 2.9 ± 1.7 | 0.425 |
| Adjuvant treatment, n (%) | 59 (83.1) | 33 (78.6) | 0.620 | 35 (83.3) | 33 (78.6) | 0.578 |
nCRT neoadjuvant chemoradiotherapy, MIS minimally invasive surgery, BMI body mass index, ASA American society of anesthesiologists, HTN hypertension, DM diabetes mellitus, IHD ischemic heart disease, COPD chronic obstructive pulmonary disease, CEA carcinoembryonic antigen, AV anal verge.